Robert James

Bio

Rob James manages DFJ Esprit’s portfolio of healthcare and medical technology investments. Since joining Esprit in 1998, he has been involved in a number of successful transactions including the exits from Oxford Biomedica and DNA Research Innovations. Rob manages DFJ Esprit’s investments in Oxford Immunotec, Kiadis Pharmaceuticals and Avantium. Prior to his time in venture capital, Robert worked for seven years commercialising cancer therapeutics and diagnostics arising from the research conducted by Cancer Research UK. He was responsible for licensing Temodal to Schering Plough (generating annual sales in excess of $600m) and Trovax to Oxford Biomedica. He has also served on the BVCA Technology Committee for four years. Rob graduated with a genetics degree from Sheffield University and a biochemistry PhD from the University of London.

Career

---

	DFJ Esprit LLP Venture capital firm. Director (past) Email: [email protected] Email: [email protected]
	Prelude Ventures Ltd N/A (past)